The most popular stories of the week on AJMC®.
CDC Warns That COVID-19 Is Likely Headed Toward Pandemic Stage, Could Affect US Schools, Businesses
It’s not a question of when coronavirus becomes a worldwide pandemic, but when, the CDC said Tuesday.
Longer Time to First Treatment Beneficial for Breast Cancer
When time to first treatment ranged from 31 to 90 days for patients with breast cancer, doctors had more time for extensive diagnostic workups without compromising survival rates.
Oncology Care First Is a Big Step Toward Bundled Payments in Cancer Care, Authors Say
While there are similarities to the Oncology Care Model, the new model has features “that could have a substantial impact on practices that choose to participate,” the authors write.
Mammography in Women Older Than 75 Does Not Confer an Additional Survival Benefit
Recommendations abound for when women at average risk for breast cancer should begin yearly mammography screening, ranging from age 40 to 50. Questions remain, however, on the optimal age at which to stop. However, with over 50% of women older than age 75 still undergoing mammography, is there a truly safe age at which to stop what has been shown to be a life-saving practice if it does not decrease their mortality from breast cancer?
FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD
The FDA approved Eli Lilly’s dulaglutide (Trulicity) for the reduction of major adverse cardiovascular events in adults with type 2 diabetes (T2D), with and without established cardiovascular disease (CVD)
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen